Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)

Market Cap	48.64M -23.8%
Revenue (ttm)	42.69M +40.6%
Net Income	-22.93M
EPS	-0.75
Shares Out	30.40M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	177,986
Open	1.605
Previous Close	1.665
Day's Range	1.530 - 1.725
52-Week Range	0.760 - 7.880
Beta	1.30
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2026

About STO:NEWBRY

Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2020
• Employees: 7
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: NEWBRY

Financial Performance

In fiscal year 2026, STO:NEWBRY's revenue was 44.39 million, an increase of 40.58% compared to the previous year's 31.57 million. Losses were -22.93 million, -4.01% less than in 2025.

Data Sources: S&P Global Market Intelligence and QUODD

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by QUODD.

Last checked:

Nov 5, 2026

Data Sources Report a data error